All In Biotech

Drug Trial Radar · NCT02914561

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Dec 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,372 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,372

Actual

Start

Oct 31, 2016

Primary completion

Nov 11, 2022

Study completion Nov 11, 2022

Sponsor

Lead sponsor
Lakefront Biotherapeutics NVIndustry
Sponsor type
Industry
Collaborators
Gilead Sciences
First posted
Sep 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to enter a separate long-term extension (LTE) study (Study GS-US-419-3896).

Conditions

  • Crohn's Disease

Interventions

  • FilgotinibDrug

    Filgotinib tablets administered orally once daily.

  • PlaceboOther

    Placebo administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Induction Study: Percentage of Participants Who Achieved Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 10Time frame: Week 10
  2. Induction Study: Percentage of Participants Who Achieved Endoscopic Response at Week 10Time frame: Week 10
  3. Maintenance Study: Percentage of Participants Who Achieved Clinical Remission by CDAI at Week 58Time frame: Week 58
  4. Maintenance Study: Percentage of Participants Who Achieved Endoscopic Response at Week 58Time frame: Week 58

Locations

513 sites in 41 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists of the Southeast

    Dothan, Alabama

  • Arizona Digestive Health - Sun City

    Sun City, Arizona

  • Southern California Research Center, Inc.

    Coronado, California

  • VVCRD Research

    Garden Grove, California

  • UC San Diego Health System

    La Jolla, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Inland Empire Clinical Trials, LLC

    Rialto, California

  • Kaiser Permanente

    San Francisco, California

  • Clearview Medical Research, LLC

    Santa Clarita, California

  • University of Colorado Denver and Hospital

    Aurora, Colorado

  • South Denver Gastroenterology, PC

    Lone Tree, Colorado

  • Connecticut GI, PC-Research Division

    Farmington, Connecticut

  • Medstar Georgetown University Hospital (Patient Exams)

    Washington D.C., District of Columbia

  • Advanced Research, LLC

    Coral Springs, Florida

  • UF Clinical Research Center

    Gainesville, Florida

  • Florida Research Institute

    Lakewood Rch, Florida

  • Florida Center for Gastroenterology

    Largo, Florida

  • University of Miami Crohn's and Colitis Center

    Miami, Florida

  • Advanced Pharma CR

    Miami, Florida

  • Cordova Research Institute

    Miami, Florida

  • Vista Health Research, LLC

    Miami, Florida

  • Gastroenterology Group of Naples

    Naples, Florida

  • Center for Interventional Endoscopy - AdventHealth Orlando

    Orlando, Florida

  • Gulf Region Clinical Research Institute

    Pensacola, Florida

  • Advanced Medical Research Center

    Port Orange, Florida

  • Tampa General Hospital

    Tampa, Florida

  • Shafran Gastroenterology Center

    Winter Park, Florida

  • Florida Medical Clinic, P.A.

    Zephyrhills, Florida

  • Gastroenterology Associates of Central Georgia, LLC

    Macon, Georgia

  • Gastrointestinal Specialists of Georgia

    Marietta, Georgia

  • Atlanta Gastroenterology Specialist, PC

    Suwanee, Georgia

  • Illinois Gastroenterology Group - Arlington Heights

    Arlington Heights, Illinois

  • Northwestern University, Feinberg School of Medicine

    Chicago, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • Illinois Gastroenterology Group - Gurnee

    Gurnee, Illinois

  • Indiana University Health University Hospital

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Louisville, School of Medicine

    Louisville, Kentucky

  • Delta Research Partners, LLC

    Monroe, Louisiana

Showing 40 of 513 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.